Cardiogenic shock remains a major challenge in acute cardiovascular care. Although the mortality of a ST segment elevation myocardial infarction (STEMI) has dramatically declined during the last halve century from more than 40% before the introduction of coronary care units (CCU) to less than 10% in the current era of well-organized STEMI networks 1 the mortality of cardiogenic shock remains unacceptably high, in a range from 40-60%. 2 An accurate view on the present-day incidence and outcome of cardiogenic shock is provided in this issue by an analysis of large contemporary STEMI cohort admitted for primary percutaneous coronary intervention (PCI) during a full year at two tertiary heart centres that cover two-thirds of the population of Denmark. 3 Cardiogenic shock was observed in one out of ten STEMI patients and is most often present already on admission (56%) whereas only a small portion of the patients (28%) developed shock after transfer from the cathlab to the ward. In spite of appropriate interventions, monitoring and treatment in the CCU or in the intensive cardiac care unit (ICCU) the 30-day mortality is still at approximately 50%. Similar findings are reported from a 10-year survey of all primary PCI's performed at the 8 Heart Attack Centres that cover the whole metropolitan area of London UK. 4 Consistently high mortality rates of 45-70% were observed over the entire course of the study. Completely in line with recent randomised trials and metaanalyses, intra-aortic balloon pump (IABP) therapy was not associated with a reduction in mortality. Intriguingly the proportion of STEMI patients developing cardiogenic shock increased progressively during the survey: from 7.0% in 2005 to 13% in 2015. Increasing rates of cardiogenic shock over recent years already have been reported by other large contemporary studies from both the USA 5 and the UK 6 . The cause of the progressively increasing rates of cardiogenic shock is not well examined but a possible explanation could be that the more efficient logistics of the prehospital diagnosis and transport of STEMI patients and the more successful resuscitation of cardiac arrest patients brings more critical patients into the hospital who otherwise would have succumbed out of hospital. The studies on the contemporary incidence and persisting high mortality from Denmark and the UK clearly demonstrate that there is an increasingly unmet need to improve the clinical outcome of cardiogenic shock complicating STEMI.
As the mortality of cardiogenic shock peaks within the first 48hours after admission it is important to timely identify the patients who are the highest risk. From the Danish survey we learn that being comatose after resuscitation from cardiac arrest (OR 17.04), previous stroke (OR 4.51), anterior STEMI (OR 3.43) and a longer time from symptom debut to intervention (OR for twofold increase 1.35) are the strongest independent predictors of 30 day mortality in cardiogenic shock. 3 It is important to assess the mental status on admission as it is a manifestation of tissue hypoperfusion in cardiogenic shock. An altered mental status was detected by bedside clinical examination in two thirds of the cardiogenic shock patients included in the CardShock study (NCT01374867 at www.clinicaltrials.gov) a European multicentre, prospective, observational study conducted between 2010 and 2012 7 The presence of an altered mental status was strongly associated with a lower arterial pH and resulted in more than twofold increase of in-hospital and short-term mortality. The importance of biochemical changes reflecting inadequate tissue perfusion as markers in the early prognostication is confirmed by a retrospective analysis of 165 consecutive cardiogenic shock patients treated at the Bern University Hospital. 8 Baseline serum bicarbonate levels on admission to the ICCU independently predicted short-term mortality. Given the widespread presence of blood gas analysers in ICCUs, baseline serum bicarbonate levels and arterial pH should be used as additional biomarkers for the early identification of cardiogenic shock patients at high risk.
Early revascularisation is the cornerstone of the management of cardiogenic shock complicating acute myocardial Cardiogenic shock: the next frontier in acute cardiovascular care! infarction. Based on the SHOCK trial 9 that showed a significant reduction of the 6-month mortality early revascularisation aiming at a complete revascularisation in patients with multivessel disease has been recommended by several generations of guidelines on the management of STEMI. As most of the patients with multivessel disease in the SHOCK trial were treated by balloon angioplasty of the culprit vessel only the evidence for recommending a complete revascularisation in cardiogenic shock patients with multivessel disease was rather weak. In this issue a meta-analysis based on 10 nonrandomized cohort studies on the interventional treatment of STEMI patients with cardiogenic shock and multivessel disease showed that multivessel PCI is associated with a significantly higher (+26%) short term (≤ 30 days) mortality than the patients in whom only the culprit artery was treated. 10 This finding has recently been confirmed by the randomized CULPRIT-SHOCK trial that showed a significantly lower (-16%) short term mortality in the patients treated by culprit-lesion-only PCI than in the patients treated by immediate multivessel PCI. 11 The ESC guidelines on the management of STEMI recommend to consider the short-term use of percutaneous mechanical circulatory support devices (intra-cardiac axial flow pumps and arterial-venous extracorporeal membrane oxygenation(AV-ECMO)) in refractory cardiogenic shock in order to stabilize the patients and preserve organ perfusion (oxygenation) as a bridge to recovery of myocardial function, cardiac transplantation, or even LV assist device destination therapy. 12 This recommendation is based on expert consensus as the scientific evidence regarding the benefits of these types of mechanical support is lacking. A small exploratory trial with the Impella CP percutaneous circulatory support device did indeed not find any benefit compared with IABP in STEMI complicated by cardiogenic shock. 13 A recent meta-analysis of 4 small randomized trials comparing percutaneous active mechanical support with either the Tandem Heart TM or Impella to standard therapy with IABP failed to demonstrate any mortality benefit in patients with cardiogenic shock complicating STEMI although active support significantly increased the mean arterial pressure and decreased arterial lactate. 14 Active mechanical support was associated with an excess of bleeding complications what may explain in part the absence of a mortality benefit despite of a clear hemodynamic and metabolic improvement compared to standard therapy with IABP.
In addition of the type of mechanical support also the timing of its initiation may have an effect on clinical outcome of cardiogenic shock. Most often mechanical support is installed relatively late after admission to the ICCU when it becomes clear that revascularization and the escalating use of inotropes and vasopressors have failed to improve the hemodynamic condition of the patient. It has . Right: Kaplan Meier curves for patients admitted for acute coronary angiography with suspected STEMI who deteriorate into cardiogenic shock (CS) and not. 3 been hypothesized that shortening the "door to unloading" and "door to support" time may allow a more effective reperfusion therapy in STEMI patients presenting in cardiogenic shock. 15 For this purpose we need the development of dedicated regional systems of care for cardiogenic shock that that allow immediate transfer of patients to advanced cardiogenic shock centers. 16 Only by reducing the 'door to support' time within these regional networks cardiogenic shock patients may be treated before they spiral into irreversible hemodynamic & metabolic shock. The feasibility of a regional hub and spoke cardiogenic shock network has been demonstrated by the French cardiac RESCUE study that transferred cardiogenic shock patients to central hub center using a mobile ECMO team. 17 The single-center study performed at the Odense University Hospital, Denmark confirms the feasibility of using the Impella device for short-term mechanical support in the acute setting of cardiogenic shock at an acceptable rate of complications. 18 Interestingly, the lower mortality observed in the group of STEMI patients in whom the device was implanted before PCI supports the earlier proposed concept of the "door to unload strategy" for the management of cardiogenic shock patients: first unloading the left ventricle by mechanical support followed by urgent primary reperfusion is hypothesized to reduce the myocardial oxygen demand what may lead to a lower propensity for reperfusion injury after revascularization. [19] [20] [21] Peripheral VA-ECMO is increasingly used as a method for temporary mechanical cardiac support for refractory cardiogenic shock complicating STEMI. Retrograde VA-ECMO blood flow in the aorta results in a marked increase of left ventricular afterload that may lead to the development of hydrostatic pulmonary oedema in patients with a depressed left ventricular systolic function. Concomitant use of IABP with deflation during systole results in afterload reduction that may compensate for the VA-ECMO related afterload increase. In a retrospective single-centre study performed at the Hôpital Pitié-Salpêtrière, France, combining IABP with peripheral VA-ECMO was associated with a 60% lower risk of hydrostatic pulmonary oedema and more days off mechanical ventilation under VA-ECMO. 22 Another method for unloading the left heart during VA-ECMO is the transcatheter creation of an atrial septal defect. From a retrospective analysis of the experience with percutaneous balloon atrioseptostomy performed in patients under support with VA-ECMO for cardiogenic shock at 4 tertiary institutions in London UK and France we learn that this is a safe and efficient strategy for decompressing the left heart. 23 No other condition than cardiogenic shock complicating a STEMI illustrates better the need of a subspecialty of acute cardiovascular care cardiologists working together with emergency physicians, other critical care physicians, cardiac surgeons and last but not least nurses in a network ranging from the prehospital emergency medical system through the emergency department and the cathlab into the ICCU. In this issue a new position paper of the Acute Cardiovascular Care Association is published that provides an update on the definition, organisation and role of the ICCU in acute cardiovascular care. 24 
